Show simple item record

dc.contributor.authorKerrison, WGJen_US
dc.contributor.authorLee, ATJen_US
dc.contributor.authorThway, Ken_US
dc.contributor.authorJones, RLen_US
dc.contributor.authorHuang, PHen_US
dc.date.accessioned2022-05-25T13:25:03Z
dc.date.available2022-05-25T13:25:03Z
dc.date.issued2022-02-28en_US
dc.identifier.citationBiomedicines, 2022, 10 (3), pp. 573 - ?en_US
dc.identifier.issn2227-9059en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5145
dc.identifier.eissn2227-9059en_US
dc.identifier.doi10.3390/biomedicines10030573en_US
dc.description.abstractImmunotherapy in soft tissue sarcoma (STS) has experienced a surge of interest in the past decade, contributing to an expanding number of therapeutic options for this extremely heterogenous group of rare malignancies. Immune checkpoint inhibitors (CPIs) targeting the PD-1 and CTLA-4 axes have demonstrated promising responses in a select number of STS subtypes, including rarer subtypes, such as alveolar soft part sarcoma, SWI/SNF-deficient sarcomas, clear cell sarcoma, and angiosarcoma. Multiple pan-subtype sarcoma trials have facilitated the study of possible predictive biomarkers of the CPI response. It has also become apparent that certain therapies, when combined with CPIs, can enhance response rates, although the specific mechanisms of this possible synergy remain unconfirmed in STS. In addition to CPIs, several other immune targeting agents, including anti-tumour-associated macrophage and antigen-directed therapies, are now under assessment in STS with promising efficacy in some subtypes. In this article, we review the state of the art in immunotherapy in STS, highlighting the pre-clinical and clinical data available for this promising therapeutic strategy.en_US
dc.formatElectronicen_US
dc.format.extent573 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleCurrent Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-02-24en_US
rioxxterms.versionofrecord10.3390/biomedicines10030573en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2022-02-28en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBiomedicinesen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume10en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSarcoma Clinical Trials (R Jones)
icr.researchteamMolecular and Systems Oncology
dc.contributor.icrauthorHuang, Paulen_US
dc.contributor.icrauthorJones, Robinen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record